Role of HMGB1 in the induction of immune responses against dying cells;Rôle du facteur high mobility group box 1 (HMGB1) dans l'induction des réponses immunitaires dirigées contre les cellules mortes

Pathologie Biologie

Volumn 57, Issue 3, 2009, Pages 217-218

  Lolmede K ^a   Rovere Querini, P ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cancer chemo and radiotherapies; Cell death; HMGB1; Immune response; Inflammation; Innate adjuvants

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CELL DEATH; CELLULAR IMMUNITY; DENDRITIC CELL; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERNALIZATION; LYSOSOME; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHAGOCYTE; PHAGOSOME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANOXIA; CELL DEATH; CELL DIFFERENTIATION; HMGB1 PROTEIN; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 67349186899     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.07.012     Document Type: Editorial

References (5)

1. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418 (2002) 191-195
2. Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., Giazzon M., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO reports 5 (2004) 825-830
3. Dimitriu I.E., Baruah P., Valentinis B., Voll R.E., Herrmann M., Nawroth P.P., et al. Release of High Mobility Group Box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174 (2005) 7506-7515
4. Ellerman J.E., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13 (2007) 1050-1059
5. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13 (2007) 1050-1059